TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22863642

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) use
Number of subjects: 2562

Group type: EXPERIMENTAL
Intervention: High supplement users (≥3 formulations per day)
Number of subjects: 2562

Group type: COMPARATOR
Intervention: No systemic treatment
Number of subjects: 2562
Study: 18803557

Group type: EXPERIMENTAL
Intervention: Local anaesthesia (EMLA 5% cream)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 50
Study: 18036295

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 583

Group type: COMPARATOR
Intervention: No anticoagulation or antiplatelet drugs
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Overall prevalence of stroke
Number of subjects: 583
Study: 16315032

Group type: EXPERIMENTAL
Intervention: 0.5% aqueous timolol
Number of subjects: 37

Group type: COMPARATOR
Intervention: 0.1% hydrogel timolol
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Head-up tilt test
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Maximum exercise test
Number of subjects: 37
Study: 11862356

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Caffeine 600 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10203414

Group type: EXPERIMENTAL
Intervention: Cyclic group (800 mg twice daily of oral clodronate for 2 weeks every 3 months for the first 12 months)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Continuous group (400 mg of clodronate once daily for the second 12 months)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cyclic group (placebo for the second 12 months)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study: 7771828

Group type: EXPERIMENTAL
Intervention: Normothermic cardiopulmonary bypass (37 degrees C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (28 degrees to 30 degrees C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cold group (hypothermic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warm group (normothermic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass
Number of subjects: 0
Study: 2150312

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombocytopenia
Number of subjects: 0
Study: 108461

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.6 to 6.0 mg/h, mean 2.3 mg/h) over 48 hours
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no specific therapy)
Number of subjects: 38
Study: 31955285

Group type: EXPERIMENTAL
Intervention: Stool nested PCR
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stool microscopy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stool PCR
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Duodenal biopsy PCR
Number of subjects: 100
Study: 31248113

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Food insecurity in women
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Food insecurity with better health literacy
Number of subjects: 800
Study: 27997263

Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) supplementation (140ml of NO3‐rich beetroot juice containing 8.0mmol [NO3‐] for seven days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 26914336

Group type: EXPERIMENTAL
Intervention: Tzu-Yun Ointment (TYO)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Topical Steroids (TS)
Number of subjects: 33
Study: 24873022

Group type: EXPERIMENTAL
Intervention: Rejected group
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Accepted group
Number of subjects: 54
Study: 22095398

Group type: EXPERIMENTAL
Intervention: Mericitabine (RG7128) 750 mg administered bid
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mericitabine (RG7128) 1500 mg administered bid
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mericitabine (RG7128) administered qd
Number of subjects: 32
Study: 19566665

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly re-treatment
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Etanercept re-treatment
Number of subjects: 226
Study: 17685691

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CRE)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 25
Study: 15458988

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 58
Study: 11880809

Group type: EXPERIMENTAL
Intervention: High-fat diet (HIFAT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: High-carbohydrate diet (HICHO)
Number of subjects: 7
Study: 10090548

Group type: EXPERIMENTAL
Intervention: Number of fever episodes
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Age at study entry
Number of subjects: 155
Study: 10172279

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol
Number of subjects: 43

Group type: COMPARATOR
Intervention: Anesthetist-controlled sedation (ACS)
Number of subjects: 43
Study: 2104972

Group type: EXPERIMENTAL
Intervention: Group I (n = 30) - Predictive equations for TBW
Number of subjects: 44

Group type: COMPARATOR
Intervention: Group II (n = 14) - Cross-validation of predictive equations
Number of subjects: 44
Study: 323316

Group type: EXPERIMENTAL
Intervention: Kanamycin gel treatment for one week before and after dental restorations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel treatment
Number of subjects: 0
Study: 31454295

Group type: EXPERIMENTAL
Intervention: Response adaptive randomization procedures in seamless phase II/III clinical trials
Number of subjects: 0
Study: 30076459

Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention consisting of dietary counseling, physical activity, and behavioral modification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous dietetic support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher self-efficacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older partner
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High stage of change towards physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High stage of change towards weight loss
Number of subjects: 0
Study: 28605468

Group type: EXPERIMENTAL
Intervention: X358 (0.1-9 mg/kg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: X358 (3-9 mg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 25441954

Group type: EXPERIMENTAL
Intervention: Fat-containing meal (30% of calories as fat)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fat-free meal
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Meal with low MUFA:PUFA ratio (1:4)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Meal with high MUFA:PUFA ratio (4:1)
Number of subjects: 50
Study: 23567505

Group type: EXPERIMENTAL
Intervention: Leave‐One‐Out procedure
Number of subjects: 33

Group type: COMPARATOR
Intervention: Split half approach
Number of subjects: 33
Study: 21281461

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy (Group CBT) sessions
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 96
Study: 19628366

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low molecular weight heparins (LMWH)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pentasaccharides
Number of subjects: 14
Study: 16199793

Group type: EXPERIMENTAL
Intervention: Family education
Number of subjects: 101
Study: 10470568

Group type: EXPERIMENTAL
Intervention: NIPSVtc (time-cycled inspiratory pressure support ventilation)
Number of subjects: 6

Group type: COMPARATOR
Intervention: NIPSVfc (flow-cycled inspiratory pressure support ventilation)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: NIPSVtc
Number of subjects: 6
Study: 9005797

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg twice a day for 3 to 5 days, followed by oral use of the same dosage for 3 to 5 days)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg once a day for 3 to 5 days)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ofloxacin (same dosage as above for 10 days)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ofloxacin (prophylactic use)
Number of subjects: 200
Study: 1947265

Group type: EXPERIMENTAL
Intervention: Gastromiro
Number of subjects: 818

Group type: COMPARATOR
Intervention: Gastrografin
Number of subjects: 818

Group type: COMPARATOR
Intervention: Prontobarium‐CT
Number of subjects: 818
Study: 7047171

Group type: EXPERIMENTAL
Intervention: Phenoperidine (2 mg i.v.)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Diazepam (t mg i.v.)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 200
Study: 31547291

Group type: EXPERIMENTAL
Intervention: Sugar beet pectin (15 g/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 100
Study: 30073224

Group type: EXPERIMENTAL
Intervention: Egg consumption (one large egg per day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Egg substitute
Number of subjects: 42
Study: 27109459

Group type: EXPERIMENTAL
Intervention: Manual Ventilation (MV)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 48
Study: 25146586

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg, open-label, every 4 weeks for up to 7 years (total of 91 doses)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 595
Study: 22029576

Group type: EXPERIMENTAL
Intervention: Physostigmine ointment after phacoemulsification
Number of subjects: 400

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Physostigmine ointment
Number of subjects: 400
Study: 19452483

Group type: EXPERIMENTAL
Intervention: Aggressive treatment with atorvastatin (maximum 80 mg/d)
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Usual care (continuation of baseline lipid-lowering therapy)
Number of subjects: 1001
Study: 16721618

Group type: EXPERIMENTAL
Intervention: Preoperative intraarticular anesthesia (0.1 mg Fentanyl + 8 ml Bupivacain 0.5%)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Postoperative intraarticular anesthesia (0.1 mg Fentanyl + 8 ml Bupivacain 0.5%)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Femoral nerve block (20 ml Prilocain 1% + 20 ml Bupivacain 0.5%)
Number of subjects: 157
Study: 16036026

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibition (ACEI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aldosterone receptor blockade
Number of subjects: 0
Study: 12432502

Group type: EXPERIMENTAL
Intervention: Arg130Gln polymorphism of the IL‐13 gene
Number of subjects: 685
Study: 10723508

Group type: EXPERIMENTAL
Intervention: Stavudine plus didanosine or lamivudine
Number of subjects: 0
Study: 7645915

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (enoxaparin) 40 mg once daily, starting 12 hours preoperatively for 10 days
Number of subjects: 167

Group type: COMPARATOR
Intervention: Unfractionated heparin (UH) 5000 IU twice a day subcutaneously, starting two hours before operation for 10 days
Number of subjects: 167
Study: 31134665

Group type: EXPERIMENTAL
Intervention: PG-SGA SF paper version
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pt-Global app
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 59
Study: 30325305

Group type: EXPERIMENTAL
Intervention: 300mg of daily oral aspirin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 28075064

Group type: EXPERIMENTAL
Intervention: Nebivolol-valsartan SPC (5/80 mg/d)
Number of subjects: 2670

Group type: EXPERIMENTAL
Intervention: Nebivolol or valsartan monotherapy
Number of subjects: 2670

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2670

Group type: EXPERIMENTAL
Intervention: All active treatments (including SPCs, nebivolol, valsartan)
Number of subjects: 2670
Study: 26638446

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg and Ezetimibe 10 mg
Number of subjects: 18144

Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 18144
Study: 24469137

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 μg/kg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 21836103

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 2503

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 2503

Group type: EXPERIMENTAL
Intervention: ILI
Number of subjects: 2503
Study: 20111618

Group type: EXPERIMENTAL
Intervention: Melatonin and Sulodexide
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Melatonin alone
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 102
Study: 17215657

Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg/d
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg/d
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Olmesartan/HCTZ 40/12.5 mg/d
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Olmesartan/HCTZ 40/25 mg/d
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 170
Study: 15316474

Group type: EXPERIMENTAL
Intervention: Halogen light curing for 20 seconds
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plasma arc light curing for 5 seconds
Number of subjects: 30
Study: 11488316

Group type: EXPERIMENTAL
Intervention: High initial dose of budesonide (800 microg b.i.d)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Standard initial dose of budesonide (200 microg b.i.d)
Number of subjects: 169
Study: 9590413

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg or 40 mg (duodenal and gastric ulcer protocols)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rabeprazole (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H. pylori positive status
Number of subjects: 0
Study: 7921757

Group type: EXPERIMENTAL
Intervention: Efamol Marine (12 capsules daily for 9 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (12 capsules daily for 9 months)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Efamol Marine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 3246170

Group type: EXPERIMENTAL
Intervention: Single intramuscular dose of ceftriaxone 50 mg/kg
Number of subjects: 52

Group type: COMPARATOR
Intervention: 7 days of amoxicillin 12.5 mg/kg t.i.d.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 52
Study: 31747677

Group type: EXPERIMENTAL
Intervention: Diet HF (high-fat diet: 38% carbohydrates, 24% proteins, and 38% fats)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Diet LF (low-fat diet: 53% carbohydrates, 20% proteins, and 27% fats)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Diet HF
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Diet LF
Number of subjects: 283
Study: 30101580

Group type: EXPERIMENTAL
Intervention: elmex erosion protection toothpaste (group E2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: R.O.C.S. toothpaste (group E3)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: R.O.C.S. medical minerals gel (group E3)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: R.O.C.S. toothpaste (group EA3)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: elmex erosion protection toothpaste (group EA2)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No additional toothpaste (control group E1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No additional toothpaste (control group EA1)
Number of subjects: 72
Study: 27994002

Group type: EXPERIMENTAL
Intervention: Latency of response efficacy (specific health benefits accruing within 1 month)
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Interrogative cue ('Ready to be tobacco-free?')
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Self-efficacy manipulation
Number of subjects: 1669
Study: 26653722

Group type: EXPERIMENTAL
Intervention: Topical NSAID treatment on the day of surgery in the femtosecond laser group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Topical NSAID treatment on the day of surgery in the conventional cataract surgery group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Femtosecond laser cataract surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional cataract surgery
Number of subjects: 75
Study: 22548378

Group type: EXPERIMENTAL
Intervention: Positive Family Interaction Therapy (PFIT) - 12 weeks of individual child CBT plus 6 sessions of family treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard Treatment (ST) - 12 weeks of individual child CBT with weekly parent check‐ins and psychoeducation
Number of subjects: 20
Study: 21469215

Group type: EXPERIMENTAL
Intervention: Add-on mirtazapine 30 mg during a 6-week double-blind phase
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo during a 6-week double-blind phase
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Open-label add-on mirtazapine during a 6-week extension phase
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mirtazapine during the double-blind phase
Number of subjects: 41
Study: 18798752

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (TAC) with onion extract gel
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (TAC) alone
Number of subjects: 27
Study: 16391903

Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LSM)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Lifestyle modification plus Metformin (LSM + MET)
Number of subjects: 531

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 531
Study: 14664677

Group type: EXPERIMENTAL
Intervention: Standard mock-crime procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Realistic mock-crime procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type of GKT questions
Number of subjects: 0
Study: 10965417

Group type: EXPERIMENTAL
Intervention: Herbal combination therapy comprising crataegus and camphor (Korodin Herz‐Kreislauf‐Tropfen)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo identical in colour and taste to the active treatment
Number of subjects: 190
Study: 8985617

Group type: EXPERIMENTAL
Intervention: Step-Wise Interview with big dolls
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Step-Wise Interview with small, detailed dolls and props
Number of subjects: 44

Group type: COMPARATOR
Intervention: Step-Wise Interview (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Step-Wise Interview with dolls (both types)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Step-Wise Interview with small detailed toys and props
Number of subjects: 44
Study: 1281728

Group type: EXPERIMENTAL
Intervention: Terazosin 10 mg
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 6145027

Group type: EXPERIMENTAL
Intervention: UK-38,485 (specific thromboxane synthetase inhibitor)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30443999

Group type: EXPERIMENTAL
Intervention: Ticagrelor 10 mg
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Ticagrelor 45 mg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 29788511

Group type: EXPERIMENTAL
Intervention: Mid-frequency current (MF, n=12)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pulsed current (PC, n=11)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (CG, n=10)
Number of subjects: 33
Study: 27246305

Group type: EXPERIMENTAL
Intervention: Cisplatin 50mg/m2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cisplatin 60mg/m2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cisplatin 70mg/m2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cisplatin 80mg/m2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Maintenance Bevacizumab
Number of subjects: 30
Study: 24529041

Group type: EXPERIMENTAL
Intervention: Oncologist communication (expressed competence, honesty, and caring)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Oncologist communication of caring
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Oncologist communication of honesty
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Patients' own oncologist
Number of subjects: 345
Study: 21044248

Group type: EXPERIMENTAL
Intervention: Transurethral plasma vaporization of the prostate (TUVis)
Number of subjects: 52
Study: 20084109

Group type: EXPERIMENTAL
Intervention: Leucovorin (1 mg/kg daily for 12 months)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (1 mg/kg daily for 12 months)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Leucovorin with concomitant thyroxin treatment
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo with concomitant thyroxin treatment
Number of subjects: 113
Study: 16497334

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (non-remitters)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (adiponectin)
Number of subjects: 37